## Meera Mahalingam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3736660/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Skin and Adnexal Structures. , 2022, , 41-127.		0
2	Pure and Mixed Desmoplastic Melanoma Subtypes Exhibit Distinct Genetic Drivers. American Journal of Dermatopathology, 2022, 44, 466-467.	0.6	2
3	Glioblastoma and malignant melanoma: Serendipitous or anticipated association?. Neuropathology, 2021, 41, 65-71.	1.2	4
4	Reforms, Errors, and Dermatopathology Malpractice. Advances in Anatomic Pathology, 2021, Publish Ahead of Print, .	4.3	1
5	SOX-10 and S100 Negative Desmoplastic Melanoma: Apropos a Diagnostically Challenging Case. American Journal of Dermatopathology, 2020, 42, 697-699.	0.6	8
6	Poikilodermatous plaqueâ€ŀike hemangioma: A benign vasoformative entity with reproducible histopathologic and clinical features. Journal of Cutaneous Pathology, 2020, 47, 950-953.	1.3	2
7	Differing biologic behaviors of desmoplastic melanoma subtypes: Insights based on histopathologic, immunohistochemical, and genetic analyses. Journal of the American Academy of Dermatology, 2020, 83, 523-531.	1.2	8
8	Adherence to the National Comprehensive Cancer Network Criteria of Complete Circumferential Peripheral and Deep Margin Assessment in Treatment of High-Risk Basal and Squamous Cell Carcinoma. Dermatologic Surgery, 2020, 46, 1473-1480.	0.8	9
9	PD-L1 Detection—Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology. American Journal of Dermatopathology, 2019, 41, 539-565.	0.6	8
10	Necrotizing Granulomas in a Patient With Psoriasis and Sarcoidosis After Adalimumab—Medication-Induced Reaction or Reactivation of Latent Disease?. American Journal of Dermatopathology, 2019, 41, 661-666.	0.6	5
11	Immunohistochemistry as a Genetic Surrogate in Dermatopathology: Pearls and Pitfalls. Advances in Anatomic Pathology, 2019, 26, 390-420.	4.3	5
12	Laser Capture Microdissection: Insights into Methods and Applications. Methods in Molecular Biology, 2018, 1723, 1-17.	0.9	16
13	Concordance of somatic mutation profiles (BRAF, NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples. Human Pathology, 2018, 82, 206-214.	2.0	14
14	Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant. Modern Pathology, 2017, 30, 357-369.	5.5	25
15	NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma. Advances in Anatomic Pathology, 2017, 24, 1-14.	4.3	30
16	Lack of specificity of cytokeratin-15 loss in scarring alopecias. Journal of the American Academy of Dermatology, 2017, 76, e135-e136.	1.2	3
17	MSH6, Past and Present and Muir–Torre Syndrome—Connecting the Dots. American Journal of Dermatopathology, 2017, 39, 239-249.	0.6	18
18	PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. Human Pathology, 2017, 66, 13-33.	2.0	46

MEERA MAHALINGAM

#	Article	IF	CITATIONS
19	BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma. Advances in Anatomic Pathology, 2016, 23, 244-271.	4.3	19
20	Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome. Journal of the American Academy of Dermatology, 2016, 75, 595-602.	1.2	16
21	Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: analyses of 76 cases. Melanoma Research, 2016, 26, 361-366.	1.2	9
22	BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin?. Human Pathology, 2016, 52, 19-27.	2.0	15
23	Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?. Human Pathology, 2016, 53, 82-90.	2.0	16
24	Erythema nodosum of non-lower-extremity sites: a histopathologic reappraisal. Giornale Italiano Di Dermatologia E Venereologia, 2016, 151, 710-713.	0.8	0
25	Cutaneous Myopericytoma: A Report of 3 Cases and Review of the Literature. Dermatopathology (Basel,) Tj ETQ	1 1 0.78 1.5	4314 rgBT /O
26	Huntingtin interacting protein 1 as a histopathologic adjunct in the diagnosis of Merkel cell carcinoma. International Journal of Dermatology, 2015, 54, 640-647.	1.0	7
27	Desmoplastic Melanoma, Neurotropism, and Neurotrophin Receptors—What We Know and What We Do Not. Advances in Anatomic Pathology, 2015, 22, 227-241.	4.3	17
28	Mycosis Fungoides, Then and Now… Have We Travelled?. Advances in Anatomic Pathology, 2015, 22, 376-383.	4.3	2
29	Microvessel density, lymphovascular density, and lymphovascular invasion in primary cutaneous melanoma—correlation with histopathologic prognosticators and BRAF status. Human Pathology, 2015, 46, 304-312.	2.0	19
30	Perineural invasion in cutaneous squamous cell carcinoma: role of immunohistochemistry, anatomical site, and the high-affinity nerve growth factor receptor TrkA. Human Pathology, 2015, 46, 1209-1216.	2.0	10
31	Neurotrophin receptors and perineural invasion in desmoplastic melanoma. Journal of the American Academy of Dermatology, 2015, 72, 851-858.	1.2	14
32	Pseudoxanthoma Elasticum–Like Change Adjacent to a Benign Adnexal Neoplasm. American Journal of Dermatopathology, 2015, 37, 157-159.	0.6	3
33	Mutation stability in primary and metastatic melanoma: what we know and what we don't. Histology and Histopathology, 2015, 30, 763-70.	0.7	5
34	Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status. Melanoma Research, 2014, 24, 621-625.	1.2	7
35	Fever and a Solitary Papule on the Foot. JAMA Dermatology, 2014, 150, 203.	4.1	0
36	Histopathology of Keratoacanthoma Revisited. International Journal of Surgical Pathology, 2014, 22, 316-325.	0.8	1

Meera Mahalingam

#	Article	IF	CITATIONS
37	p40 exhibits better specificity than p63 in distinguishing primary skin adnexal carcinomas from cutaneous metastases. Human Pathology, 2014, 45, 1078-1083.	2.0	35
38	Skin cancer, photoprotection, and skinÂofÂcolor. Journal of the American Academy of Dermatology, 2014, 71, 586.	1.2	7
39	Protein expression of the chemokine receptor CXCR4 and its ligand CXCL12 in primary cutaneous melanoma—biomarkers of potential utility?. Human Pathology, 2014, 45, 2094-2100.	2.0	9
40	Porocarcinoma: an exceedingly rare tumor or a tumor eclipse phenomenon?—Reply. Human Pathology, 2013, 44, 449.	2.0	0
41	Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Modern Pathology, 2013, 26, 414-420.	5.5	61
42	MEN1 Is a Melanoma Tumor Suppressor That Preserves Genomic Integrity by Stimulating Transcription of Genes That Promote Homologous Recombination-Directed DNA Repair. Molecular and Cellular Biology, 2013, 33, 2635-2647.	2.3	43
43	Dermatopathology, then and now $\hat{a} \in$ '' have we travelled?. Expert Review of Dermatology, 2013, 8, 585-587.	0.3	0
44	c-myc and Cutaneous Vascular Neoplasms. American Journal of Dermatopathology, 2013, 35, 364-369.	0.6	17
45	The Grenz Zone. American Journal of Dermatopathology, 2013, 35, 83-91.	0.6	17
46	Profiling of ABC transporters ABCB5, ABCF2 and nestin-positive stem cells in nevi, in situ and invasive melanoma. Modern Pathology, 2012, 25, 1169-1175.	5.5	27
47	Adenomatous Eccrine Metaplasia—A Novel Reaction Pattern. American Journal of Dermatopathology, 2012, 34, 47-53.	0.6	7
48	Lack of Correlation Between Immunohistochemical Expression of CKIT and KIT Mutations in Atypical Acral Nevi. American Journal of Dermatopathology, 2012, 34, 41-46.	0.6	14
49	Expression of Gelatinases (MMP-2, MMP-9) and Gelatinase Activator (MMP-14) in Actinic Keratosis and in In Situ and Invasive Squamous Cell Carcinoma. American Journal of Dermatopathology, 2012, 34, 723-728.	0.6	21
50	Cutaneous Clear Cell Neoplasms. American Journal of Dermatopathology, 2012, 34, 237-254.	0.6	20
51	Levamisole-Induced Vasculopathy. American Journal of Dermatopathology, 2012, 34, 208-213.	0.6	28
52	Matrix Metalloproteinases in Health and Disease: Insights From Dermatopathology. American Journal of Dermatopathology, 2012, 34, 565-579.	0.6	20
53	Human papillomavirus and cutaneous squamous cell carcinoma: the dilemma continues. Expert Review of Dermatology, 2012, 7, 159-170.	0.3	1
54	Neuropilin-2: a novel biomarker for malignant melanoma?. Human Pathology, 2012, 43, 381-389.	2.0	28

#	Article	IF	CITATIONS
55	An immunohistochemical comparison of cytokeratin 7, cytokeratin 15, cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in differentiating porocarcinoma from squamous cell carcinoma. Human Pathology, 2012, 43, 1265-1272.	2.0	44
56	Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal. Modern Pathology, 2012, 25, 505-515.	5.5	47
57	Methodology matters, but…. Journal of Cutaneous Pathology, 2012, 39, 78-79.	1.3	0
58	Primary cutaneous CD56 positive lymphoma: a diagnostic conundrum in an unusual case of lymphoma. Journal of Cutaneous Pathology, 2012, 39, 540-544.	1.3	10
59	Reactive granular histiocytosis secondary to arthroplasty prosthesis: a novel reaction pattern. Journal of Cutaneous Pathology, 2012, 39, 558-561.	1.3	5
60	Psoriatic alopecia - fact or fiction? A clinicohistopathologic reappraisal. Indian Journal of Dermatology, Venereology and Leprology, 2012, 78, 611.	0.6	16
61	Stem cell markers (cytokeratin 15, cytokeratin 19 and p63) in in situ and invasive cutaneous epithelial lesions. Modern Pathology, 2011, 24, 90-97.	5.5	47
62	Somatic mutations in GNAQ in amelanotic/hypomelanotic blue nevi. Human Pathology, 2011, 42, 136-140.	2.0	29
63	Molecular Diagnostics—An Emerging Frontier in Dermatopathology. American Journal of Dermatopathology, 2011, 33, 1-16.	0.6	17
64	Desmoplasia: not always a bad thing. Histopathology, 2011, 58, 643-659.	2.9	21
65	šlowly growing, ulcerating nodule on the posterior ankle . Wounds, 2011, 23, 320-1.	0.5	Ο
66	D2-40 Expression in Primary Scarring and Nonscarring Alopecia. American Journal of Dermatopathology, 2010, 32, 427-431.	0.6	3
67	Nestin-Positive Stem Cells in Neurofibromas From Patients With Neurofibromatosis Type 1-Tumorigenic or Incidental?. American Journal of Dermatopathology, 2010, 32, 574-577.	0.6	4
68	When Dead Cells Tell Tales-Cutaneous Involvement by Precursor T-Cell Acute Lymphoblastic Lymphoma With an Uncommon Phenotype. American Journal of Dermatopathology, 2010, 32, 183-186.	0.6	4
69	Perineural Involvement: What Does it Mean?. American Journal of Dermatopathology, 2010, 32, 469-476.	0.6	13
70	Expression of Stem-Cell Markers (Cytokeratin 15 and Nestin) in Primary Adnexal Neoplasms-Clues to Etiopathogenesis. American Journal of Dermatopathology, 2010, 32, 774-779.	0.6	18
71	Epidermotropic Metastatic Mucoepidermoid Carcinoma. American Journal of Dermatopathology, 2010, 32, 505-508.	0.6	5
72	Anaplastic Kaposi's sarcoma: an uncommon histologic phenotype with an aggressive clinical course. Journal of Cutaneous Pathology, 2010, 37, 1088-1091.	1.3	16

MEERA MAHALINGAM

#	Article	IF	CITATIONS
73	Oncogenic <i>BRAF</i> and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevomelanocytic proliferations. Journal of Cutaneous Pathology, 2010, 37, 344-349.	1.3	17
74	Immunohistochemistry in the diagnosis of cutaneous neoplasms. Future Oncology, 2010, 6, 93-109.	2.4	8
75	Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma. Modern Pathology, 2010, 23, 1535-1543.	5.5	53
76	The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin. Modern Pathology, 2010, 23, 713-719.	5.5	84
77	Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7—challenging the concept of dysplastic nevi as precursor lesions?. Human Pathology, 2010, 41, 886-894.	2.0	27
78	Role for IGFBP7 in Senescence Induction by BRAF. Cell, 2010, 141, 746-747.	28.9	40
79	Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Molecular Cancer Therapeutics, 2009, 8, 3009-3014.	4.1	42
80	When a negative is a positive!. Journal of Cutaneous Pathology, 2009, 36, 1022-1023.	1.3	0
81	Morphometric analyses of elastic tissue fibers in dermatofibroma: clues to etiopathogenesis?. Journal of Cutaneous Pathology, 2009, 36, 1083-1088.	1.3	1
82	Cutaneous sebaceous neoplasms as markers of Muirâ€Torre syndrome: a diagnostic algorithm. Journal of Cutaneous Pathology, 2009, 36, 613-619.	1.3	118
83	Tumor of the Follicular Infundibulum: An Epidermal Reaction Pattern?. American Journal of Dermatopathology, 2009, 31, 626-633.	0.6	36
84	Prognostic Value of E-Cadherin, β-Catenin, CD44v6, and HER2/neu in Metastatic Cutaneous Adenocarcinoma. Archives of Pathology and Laboratory Medicine, 2009, 133, 1285-1290.	2.5	6
85	Clinicopathologic challenge. International Journal of Dermatology, 2008, 47, 13-14.	1.0	3
86	CD99 – much ado about nothing?*. Journal of Cutaneous Pathology, 2008, 35, 86-87.	1.3	4
87	Nodular vasculitis – a novel cutaneous manifestation of autoimmune colitis. Journal of Cutaneous Pathology, 2008, 35, 315-319.	1.3	14
88	Adverse cutaneous reactions to soft tissue fillers – a review of the histological features. Journal of Cutaneous Pathology, 2008, 35, 536-548.	1.3	99
89	Involvement of the bulge region in primary scarring alopecia. Journal of Cutaneous Pathology, 2008, 35, 922-925.	1.3	50
90	Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. Modern Pathology, 2008, 21, 31-38.	5.5	55

Meera Mahalingam

#	Article	IF	CITATIONS
91	MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir–Torre syndrome. Modern Pathology, 2008, 21, 159-164.	5.5	71
92	Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Modern Pathology, 2008, 21, 178-185.	5.5	106
93	Quality assurance and continuing medical education in dermatopathology – the ASDP way. Journal of Cutaneous Pathology, 2008, 35, 516-519.	1.3	3
94	Congenital Darier disease. Journal of the American Academy of Dermatology, 2008, 59, S50-S51.	1.2	9
95	Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7. Cell, 2008, 132, 363-374.	28.9	787
96	Pruritic Patches on the Back and Papules on the Legs—Quiz Case. Archives of Dermatology, 2007, 143, 255-60.	1.4	3
97	Verrucous carcinoma of the scalp. Journal of the American Academy of Dermatology, 2007, 56, 506-507.	1.2	27
98	Cutaneous oncocytoma ? a report of three cases and review of the literature. Journal of Cutaneous Pathology, 2007, 34, 355-359.	1.3	21
99	Ductal eccrine carcinoma with squamous differentiation: apropos a case. Journal of Cutaneous Pathology, 2007, 34, 503-507.	1.3	28
100	Histopathology of Gottron?s papules ? utility in diagnosing dermatomyositis. Journal of Cutaneous Pathology, 2007, 34, 793-796.	1.3	24
101	Acanthomatous superficial sebaceous hamartoma? A study of six cases with clarification of the nomenclature. Journal of Cutaneous Pathology, 2007, 34, 865-870.	1.3	16
102	Massive exophytic abscesses and fibrotic masses of the chin: A variant of the follicular occlusion triad. Journal of the American Academy of Dermatology, 2003, 48, S47-S50.	1.2	9
103	Morphea-Like Tattoo Reaction. American Journal of Dermatopathology, 2002, 24, 392-395.	0.6	45
104	Amyloidosis of the Auricular Concha: An Uncommon Variant of Localized Cutaneous Amyloidosis. American Journal of Dermatopathology, 2002, 24, 447-448.	0.6	11
105	Atypical Pilar Leiomyoma. American Journal of Dermatopathology, 2001, 23, 299-303.	0.6	31
106	Expression of PGP 9.5 in granular cell nerve sheath tumors: an immunohistochemical study of six cases. Journal of Cutaneous Pathology, 2001, 28, 282-286.	1.3	34
107	Tumor of the follicular infundibulum with sebaceous differentiation. Journal of Cutaneous Pathology, 2001, 28, 314-317.	1.3	28
108	Intra-epidermal and intra-dermal sebocrine adenoma with cystic degeneration and hemorrhage. Journal of Cutaneous Pathology, 2000, 27, 472-475.	1.3	9

#	Article	IF	CITATIONS
109	Letter to the editor. Cytometry, 1996, 24, 190-190.	1.8	3
110	Epstein-Barr virus and autoimmune hepatitis. Lancet, The, 1995, 346, 913.	13.7	1
111	Co-expression of CD45RA (naive) and CD45RO (memory) T-cell markers. Lancet, The, 1994, 343, 424.	13.7	13
112	Inhibition of Tumor Cell-Induced Platelet Aggregation and Experimental Tumor Metastasis by the Synthetic Gly-Arg-Gly-Asp-Ser Peptide. Journal of the National Cancer Institute, 1988, 80, 1461-1466.	6.3	49
113	Dermatology Clinical Case Modules: 62-Year-Old Man With a Facial Growth. MedEdPORTAL: the Journal of Teaching and Learning Resources, 0, , .	1.2	1
114	Dermatology Clinical Case Modules: 70-Year-Old Man With a Red Crusty Bump on His Right Arm. MedEdPORTAL: the Journal of Teaching and Learning Resources, 0, , .	1.2	1
115	Dermatology Clinical Case Modules: 40-Year-Old Woman With a Dark Mole. MedEdPORTAL: the Journal of Teaching and Learning Resources, 0, , .	1.2	1